PURPOSE: Preoperative therapy in borderline resectable pancreatic cancer (BRPC) is intended to increase R0 resection rates. An optimal approach in BRPC is yet to be defined. METHODS AND MATERIALS: Patients with BRPC, confirmed adenocarcinoma, performance status ≤1, and adequate organ function enrolled in a single-institution, phase 2 trial. Patients received FOLFIRINOX × 6 cycles, then radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2 over 100 minutes) followed by 2 additional gemcitabine infusions. Computed tomography scans were performed at 2-month intervals during treatment. Patients without distant disease were offered surgical exploration. The primary objective was R0 resection rate with an alternate hypothesis of 55%. Secondary objectives included median progression-free survival (PFS), median overall survival (OS), response rate, and safety. The trial registration number is NCT01661088. RESULTS: Twenty-five patients with median age of 60 years (range, 47-77 years) enrolled from November 2011 through January 2017. Twenty-one (84%) completed FOLFIRINOX and 19 (76%) completed all protocol therapy. Treatment-related grade 3 to 4 toxicities included neutropenia (40%), nausea and vomiting (28%), diarrhea (16%), and fatigue (12%). Eighteen patients (72%) underwent laparotomy, 13 (52%) were resected (all R0). The median PFS and OS in 25 patients were 13.1 months (95% confidence interval [CI], 7.3-24.7) and 24.4 months (95% CI, 12.6-40.0), respectively. For resected patients, median PFS was 21.6 months (95% CI, 8.2-37.1) and OS was 37.1 months (95% CI, 15.4-not reached). CONCLUSIONS: Neoadjuvant therapy with FOLFIRINOX, followed by intensity modulated radiation therapy concurrent with fixed-dose-rate gemcitabine in BRPC is feasible and tolerated. Although the alternate hypothesis was not met, the OS of the resected cohort was favorable.
PURPOSE: Preoperative therapy in borderline resectable pancreatic cancer (BRPC) is intended to increase R0 resection rates. An optimal approach in BRPC is yet to be defined. METHODS AND MATERIALS: Patients with BRPC, confirmed adenocarcinoma, performance status ≤1, and adequate organ function enrolled in a single-institution, phase 2 trial. Patients received FOLFIRINOX × 6 cycles, then radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2 over 100 minutes) followed by 2 additional gemcitabine infusions. Computed tomography scans were performed at 2-month intervals during treatment. Patients without distant disease were offered surgical exploration. The primary objective was R0 resection rate with an alternate hypothesis of 55%. Secondary objectives included median progression-free survival (PFS), median overall survival (OS), response rate, and safety. The trial registration number is NCT01661088. RESULTS: Twenty-five patients with median age of 60 years (range, 47-77 years) enrolled from November 2011 through January 2017. Twenty-one (84%) completed FOLFIRINOX and 19 (76%) completed all protocol therapy. Treatment-related grade 3 to 4 toxicities included neutropenia (40%), nausea and vomiting (28%), diarrhea (16%), and fatigue (12%). Eighteen patients (72%) underwent laparotomy, 13 (52%) were resected (all R0). The median PFS and OS in 25 patients were 13.1 months (95% confidence interval [CI], 7.3-24.7) and 24.4 months (95% CI, 12.6-40.0), respectively. For resected patients, median PFS was 21.6 months (95% CI, 8.2-37.1) and OS was 37.1 months (95% CI, 15.4-not reached). CONCLUSIONS: Neoadjuvant therapy with FOLFIRINOX, followed by intensity modulated radiation therapy concurrent with fixed-dose-rate gemcitabine in BRPC is feasible and tolerated. Although the alternate hypothesis was not met, the OS of the resected cohort was favorable.
Authors: Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan Journal: Ann Surg Oncol Date: 2009-04-24 Impact factor: 5.344
Authors: Mark S Talamonti; William Small; Mary F Mulcahy; Jeffrey D Wayne; Vikram Attaluri; Lisa M Colletti; Mark M Zalupski; John P Hoffman; Gary M Freedman; Timothy J Kinsella; Philip A Philip; Cornelius J McGinn Journal: Ann Surg Oncol Date: 2006-01-19 Impact factor: 5.344
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Jean-Luc Van Laethem; Pascal Hammel; Françoise Mornex; David Azria; Geertjan Van Tienhoven; Philippe Vergauwe; Marc Peeters; Marc Polus; Michel Praet; Murielle Mauer; Laurence Collette; Volker Budach; Manfred Lutz; Eric Van Cutsem; Karin Haustermans Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Somnath Mukherjee; Christopher N Hurt; John Bridgewater; Stephen Falk; Sebastian Cummins; Harpreet Wasan; Tom Crosby; Catherine Jephcott; Rajarshi Roy; Ganesh Radhakrishna; Alec McDonald; Ruby Ray; George Joseph; John Staffurth; Ross A Abrams; Gareth Griffiths; Tim Maughan Journal: Lancet Oncol Date: 2013-03-06 Impact factor: 41.316
Authors: Dany Barrak; Anthony M Villano; Nicole Villafane-Ferriol; Leah G Stockton; Maureen V Hill; Mengying Deng; Elizabeth A Handorf; Sanjay S Reddy Journal: Eur J Surg Oncol Date: 2022-01-05 Impact factor: 4.037
Authors: Christopher Gromisch; Motaz Qadan; Mariana Albuquerque Machado; Kebin Liu; Yolonda Colson; Mark W Grinstaff Journal: Cancer Res Date: 2020-03-27 Impact factor: 12.701
Authors: Adam C Mueller; Miles Piper; Andrew Goodspeed; Shiv Bhuvane; Jason S Williams; Shilpa Bhatia; Andy V Phan; Benjamin Van Court; Kathryn L Zolman; Brisa Peña; Ayman J Oweida; Sara Zakem; Cheryl Meguid; Michael W Knitz; Laurel Darragh; Thomas E Bickett; Jacob Gadwa; Luisa Mestroni; Matthew R G Taylor; Kimberly R Jordan; Peter Dempsey; M Scott Lucia; Martin D McCarter; Marco Del Chiaro; Wells A Messersmith; Richard D Schulick; Karyn A Goodman; Michael J Gough; Casey S Greene; James C Costello; Antonio Galveo Neto; David Lagares; Kirk C Hansen; Adrie Van Bokhoven; Sana D Karam Journal: Cancer Res Date: 2021-02-01 Impact factor: 12.701
Authors: Cyrus Chargari; Antonin Levy; Xavier Paoletti; Jean-Charles Soria; Christophe Massard; Ralph R Weichselbaum; Eric Deutsch Journal: Clin Cancer Res Date: 2020-05-14 Impact factor: 12.531
Authors: Robyn D Gartrell; Thomas Enzler; Pan S Kim; Benjamin T Fullerton; Ladan Fazlollahi; Andrew X Chen; Hanna E Minns; Subha Perni; Stuart P Weisberg; Emanuelle M Rizk; Samuel Wang; Eun Jeong Oh; Xinzheng V Guo; Codruta Chiuzan; Gulam A Manji; Susan E Bates; John Chabot; Beth Schrope; Michael Kluger; Jean Emond; Raul Rabadán; Donna Farber; Helen E Remotti; David P Horowitz; Yvonne M Saenger Journal: Oncoimmunology Date: 2022-05-05 Impact factor: 7.723
Authors: Joseph A Miccio; Wesley J Talcott; Timil Patel; Henry S Park; Michael Cecchini; Ronald R Salem; Sajid A Khan; Stacey Stein; Jeremy S Kortmansky; Jill Lacy; Amol Narang; Joseph Herman; Salma K Jabbour; Christopher L Hallemeier; Kimberly Johung; Krishan R Jethwa Journal: Clin Transl Radiat Oncol Date: 2020-12-16
Authors: Quisette P Janssen; Jacob L van Dam; Isabelle G Kivits; Marc G Besselink; Casper H J van Eijck; Marjolein Y V Homs; Joost J M E Nuyttens; Hongchao Qi; Hjalmar J van Santvoort; Alice C Wei; Roeland F de Wilde; Johanna W Wilmink; Geertjan van Tienhoven; Bas Groot Koerkamp Journal: Ann Surg Oncol Date: 2021-06-17 Impact factor: 5.344